Status:
COMPLETED
Docetaxel and Irinotecan in Gastric Cancer
Lead Sponsor:
Menoufia University
Conditions:
Stomach Cancer
Gastric Cancer
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
To assess the role of docetaxel and irinotecan combination in second line gastric cancer. The primary end point is response rate. Secondary end points are toxicity, PFS and OS.
Detailed Description
Gastric cancer is a major killer in oncology. The expected overall survival of metastatic patients is less than 2 years. Moreover, most of the patients develop cachexia and worsening of performance ov...
Eligibility Criteria
Inclusion
- Histopathological evidence of adenocarcinoma of the stomach
- Metastatic disease or locally advanced non-resectable disease
- Patients who received only one line of treatment
- Performance status 0,1,2 as per ECOG scoring system
Exclusion
- Patients who received docetaxel or irinotecan before recruitment to this study
- Multiple comorbid conditions
- Liver or kidney impairment
- Severe cachexia (sarcopenia)
Key Trial Info
Start Date :
March 5 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 9 2023
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT04770623
Start Date
March 5 2021
End Date
January 9 2023
Last Update
January 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Menoufia University, Faculty of medicine
Shibīn al Kawm, Menoufia, Egypt, 32511